Recent developments include the appointment of an interim CFO in February 2026, preliminary 2025 financial results indicating revenue growth, and multiple analyst buy recommendations supporting the company’s commercial progress.

• MDxHealth appointed Ron Kalfus as interim Chief Financial Officer effective February 26, 2026 [N1][S2].
• The company posted preliminary 2025 results with revenue growth of 20% compared to 2024, driven by increased test volumes and the acquisition of ExoDx in September 2025 [N2].
• Multiple financial analysts including TD Cowen, Lake Street, and BTIG maintained buy recommendations on MDxHealth in late 2025, reflecting positive market sentiment [N3][N4][N5].
• MDxHealth reported Q2 and Q1 2025 losses but topped revenue estimates, indicating ongoing investment in growth alongside revenue expansion [N6][N8].

MDxHealth’s suite of precision diagnostic tests addresses critical gaps in prostate cancer screening and management by improving diagnostic accuracy and reducing unnecessary invasive procedures. The acquisition of Exosome Diagnostics and integration of the Exo mdx test expands the company’s product portfolio and market reach. The company’s reimbursement coverage by Medicare and commercial payors, along with recognition in clinical guidelines, supports adoption. Continued physician and patient education efforts, along with expansion of the test menu including Monitor mdx, may enhance market penetration. Operational scale and improved fixed cost absorption contributed to improved gross margins in 2025. The company’s direct sales force and strategic partnerships provide a strong commercial channel to drive revenue growth.

MDxHealth has incurred net losses since inception and reported a net loss of $33.5 million in 2025, reflecting ongoing operating expenses exceeding revenues. The company’s liquidity, with $29.0 million in cash and equivalents and a current ratio of 1.08 as of December 31, 2025, may constrain its ability to fund operations without additional capital. The molecular diagnostics field is competitive and subject to rapid technological change, reimbursement uncertainties, and pricing pressures. Dependence on a limited number of suppliers for certain laboratory materials and equipment may pose operational risks. The company’s ability to expand reimbursement coverage and physician adoption is critical to commercial success. Management changes, including appointment of an interim CFO, may reflect transitional challenges. Continued operating losses and cash outflows raise concerns about long-term financial sustainability without successful commercialization and capital raising.

MDxHealth’s competitive strengths include a targeted menu of clinically validated tests addressing significant unmet needs in prostate cancer diagnosis and management, supported by strong reimbursement coverage including Medicare and commercial payors. The company benefits from established relationships with over 7,000 urologists and a direct sales force focused on urology networks in the United States. Its proprietary molecular diagnostic technologies, extensive biomarker library, and CAP/CLIA certified laboratory infrastructure provide technological and operational advantages. Inclusion of its tests in major clinical guidelines such as NCCN enhances clinical adoption. The company’s reimbursement strategy and commercial channel presence create barriers to entry for competitors. Additionally, MDxHealth’s management team has industry expertise and a track record of execution, supporting sustained commercial growth and product development.

• Financial Sustainability: MDxHealth has a history of net losses and significant cash outflows, with a net loss of $33.5 million in 2025 and limited cash reserves, which may impact its ability to sustain operations without additional financing.
• Reimbursement and Coverage: The company’s commercial success depends heavily on obtaining and maintaining favorable reimbursement from government and private payors, which is subject to regulatory and market uncertainties.
• Competitive and Technological Risks: The molecular diagnostics industry is highly competitive with rapid technological changes, which may affect MDxHealth’s market position and require ongoing investment in R&D.
• Supply Chain Dependencies: MDxHealth relies on a limited number of suppliers for certain critical laboratory materials and equipment, which could disrupt operations if supply issues arise.
• Operational and Management Risks: Recent management changes, including appointment of an interim CFO, and the need to execute commercial strategies effectively pose operational risks.

• MDxHealth SA is a Belgium-incorporated, commercial-stage precision diagnostics company focused on non-invasive, clinically actionable, and cost-effective urologic solutions, primarily for prostate cancer and urinary tract infections (UTIs).
• The company offers a core menu of tests: Confirm mdx, GPS mdx, and Exo mdx, providing personalized DNA and RNA insights to physicians and patients for prostate cancer diagnosis and management.
• In 2025, MDxHealth acquired Exosome Diagnostics, Inc., including the Exo mdx test and its CLIA-certified clinical laboratory, completed in September 2025.
• More than 7,000 urologists have ordered over 500,000 mdxhealth tests.
• Each core test (Confirm mdx, GPS mdx, Exo mdx) is recognized in National Comprehensive Cancer Network (NCCN) guidelines and reimbursed by Medicare.
• The company also offers Resolve mdx, a urinary tract infection test that provides patient-specific antimicrobial treatment options within 48 hours, reimbursed by Medicare and most private insurers.
• MDxHealth operates a CAP accredited, CLIA certified, and New York State Department of Health approved molecular laboratory.
• The company has a proprietary intellectual property portfolio and extensive biomarker library applicable to urology and men's health diagnostics.
• MDxHealth's strategy includes physician and patient education, expanding its test menu (including development of Monitor mdx for active surveillance), and expanding reimbursement coverage.
• The company has a direct sales force in the United States targeting urology-focused networks and evaluates distribution partners outside the US.
• Prostate cancer is a significant market opportunity, with approximately 3 million men screened annually, 500,000 biopsies, 299,000 diagnoses, and 2 million UTI cases managed by urologists annually in the US.
• Financial figures for the year ended December 31, 2025: revenue of $107.9 million, net loss of $33.5 million, basic and diluted EPS of -$0.67.
• Liquidity as of December 31, 2025: cash and cash equivalents of $29.0 million, current assets of $53.4 million, current liabilities of $49.5 million, current ratio of 1.08, and cash ratio of 0.59.
• The company has incurred net losses since inception and expects to continue incurring operating losses in the near term while investing in growth.
• MDxHealth has raised capital through equity offerings and debt facilities, with approximately $425 million raised to date.
• The company’s commercial tests have shown revenue growth driven by increased volumes and the acquisition of ExoDx in 2025.
• Management has appointed an interim Chief Financial Officer as of February 26, 2026.
• MDxHealth’s tests aim to reduce unnecessary biopsies and treatments by improving diagnostic accuracy and risk stratification for prostate cancer.
• The company’s tests have demonstrated high negative predictive values (e.g., Exo mdx has 91% NPV for clinically significant prostate cancer).
• MDxHealth’s products are reimbursed by Medicare and covered by commercial payors, supported by CPT codes and clinical guidelines.
• The company’s research and development expenses were $10.4 million in 2025, primarily related to pipeline product development.
• Capital expenditures for 2025 were $1.2 million, mainly for laboratory and IT equipment.
• The company’s headquarters are in Herstal, Belgium, with wholly owned subsidiaries in Delaware and the Netherlands.
• MDxHealth’s shares trade solely on the Nasdaq Capital Market under the ticker MDXH since December 18, 2023, following delisting from Euronext Brussels and ADS facility termination.